With SPACs' high tide long gone, Blue Water ditches second blank check voyage
The SPAC waters have been choppy for a few quarters, and the leaders of Blue Water Vaccines are joining the wave of blank-check operators ditching plans to dock their boat on Wall Street.
While the Blue Water duo of Joseph Hernandez and Jon Garfield was successful in getting their first SPAC to merge with a biotech, testosterone drug maker Clarus Therapeutics, and also take their own biotech public in February, they have decided to back out of the SPAC market, following the suit of many others.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.